Sure.
the me start. you Thanks for question. Let to
adrulipase with first. start me Let
that trials really clinical I works. did make The well. to We that year confident drug was of just we statement. the patients some that saw in that issue this the our are want
of of enzyme the way the the drug gut. And set across kind up all. the we because take patients didn't process is And -- average the is metabolized, the right some way didn't. of metabolized patients processed the just of the the The is increases enzyme protocol the board. itself pH at And unfortunately, drug through or some is an imbalance, CFA
can't take half patients of You worked where where the and patients just didn't it work. the it half
have need we decision So we've where do what some -- a we we need formulation is to consistency across and to gut. made is find that the
the what manufacturing. are beadlets, terms They've literally went manufacturing which who But micro we've actually these in perks they done has [ph]. for we of major and the contract very at beadlets. we private found So micro AbbVie done use look competitors, Nestle is that enteric to coated our organization with right done
now provide So or for it's basically release consistency patient, not at should trial. what are we working the go pH. on patients that Those And they same our a just microbeadlets manufacturing the right going of to company, and every certain it's half the process. is hope a through the third enzyme
So programs manufacturing these of some kind take time.
take a drug the we find to to have And you because got right people, have find to we food. right the enzyme hopefully -- spray coating You patients hope you that works, that to with do these the have works. these certain drying,
mixtures with test So food. you the to have
lot call in animals and get back that in before can vitro a we of we in has to into humans. what vivo, happen, testing there's So scientific, then
these manufacturing And Big three a we that quickly, you usually we're year. working half of formulation, start for worked establish right we a years, or I pretty the next into chief the and we done. years I beings, We're right said, get in we -- years. at tell two you, to that consistency Pharma you once So take the formulation, a the With first across many many, bridging found but to calling quickly. don't expect models, get found moving it'll we're when human until pretty couple small change that study all new will because what organization. that contract have
expectations going sometimes that of which every do X, the you go is sure exactly the in work. the the is is biotech, to not really Phase a that didn't is the formulation that's with away are Bad want -- -- it in we drug Big have Pharma, half adrulipase. to had, you is which lot do. good news what you're So drugs to proprietary battle we news works, The
So we're pretty confident there.
start Ukraine In that niclosamide, new let's terms coming sites and open well. that's COVID. milestones up up with for We of which last this in the compound announced progress, States got in India. week sites in trial as we the more the other will is the United our currently We've
United virus new opportunities. for good misfortune bad, the opened world, or States up For with has Delta the around that us have we to the the
how if I'm quarter year to and would it have we emergency first looks top get to the patients be outbreak So data I really If faster. the this faster, we breakthrough infections is I've the quickly in good, Hopefully, the the trial But authorization. can can't that can happens line comment able on be move done. half, and to in for next going we terms stick applying of And data to first we fact, the given trial done of faster, might sooner. get be enroll COVID. able might guidance use to we
milestones inhibitor which available checkpoint on major are colitis, filed just the would indication, IND. So the COVID
Jim committee up Pennington a Kettering a investigators and Sloan have runs, our at just name few. made steering of to Anderson Memorial that the We
are with protocol We in of review midst the them.
make to protocol sure want Xb/X we a The we we trial place the will starting in have So before trial. be announce trial. a right
We sick. going So in different? a dose little not X, why These patients sure we to are because right make it want full the is the dosing be pretty have a is Phase place. to
merging of we Bio, how the the will blown end before that sure in dosage of half proctitis quickly is the efficacy, not are right that by Phase can So go into these which is the safety. see We The moving study started But Wave get we'll X. hope or but right part the we year. of we're only have safety that. the of for we we We full this can midst make of want They patients a first the which to UT, get first study First with. the protocol now. it be company
to take today over, are to going some And obviously starting We be paperwork really. it completed. needs
that you sponsor. the of Some we're now know
the plan and investigators. the the on bodies. enrolled given Glick guidance us was to as study take possible. Gary again paperwork file was So we a FDA to study the to, all to obviously with that We'll The as getting touch regulatory quickly some And months. that need the have time. from we takes with was XX But that about going
So next we that we be the that about we months, of XX -- are months acquired, should the we so within we expect in The they the far pretty along stay should tuned. indications four study. rest with XX,
a -- a we about small gastrointestinal But will one need seven can't been bad. do. prioritize prioritize. We not there's ones. large everything there it's or do to are we what that are full company. this bunch partners at great time We're is a time. We smaller What's of will obviously that companies. lot There's eight But about not and ones of space,
an We And in it, with one and them. if face let's partner get want to they forward moving indication opportunity have they move with an us be forward. gives see somebody those to of that that touch indications will
long I Sorry, your but I question. you hope to answer answered winded
